These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35194606)

  • 1. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.
    Fang Z; Peng L; Filler R; Suzuki K; McNamara A; Lin Q; Renauer PA; Yang L; Menasche B; Sanchez A; Ren P; Xiong Q; Strine M; Clark P; Lin C; Ko AI; Grubaugh ND; Wilen CB; Chen S
    bioRxiv; 2022 Feb; ():. PubMed ID: 35194606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.
    Fang Z; Peng L; Filler R; Suzuki K; McNamara A; Lin Q; Renauer PA; Yang L; Menasche B; Sanchez A; Ren P; Xiong Q; Strine M; Clark P; Lin C; Ko AI; Grubaugh ND; Wilen CB; Chen S
    Nat Commun; 2022 Jun; 13(1):3250. PubMed ID: 35668119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
    Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH; Saini M; Wieland A; Manning KE; Ellis M; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Edara VV; Patel M; Steur C; Nooka AK; Green F; Johns MA; O'Brein F; Shanmugasundaram U; Zarnitsyna VI; Ahmed H; Nyhoff LE; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar MS; Dhodapkar MV; Ramalingam S; Ahmed R
    J Clin Oncol; 2022 Nov; 40(33):3808-3816. PubMed ID: 35759727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
    Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
    [No Abstract]   [Full Text] [Related]  

  • 7. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
    Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
    Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
    Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.
    Poh XY; Tan CW; Lee IR; Chavatte JM; Fong SW; Prince T; Hartley C; Yeoh AYY; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim C; Teo J; Lim DRX; Chia W; Hiscox JA; Ng LFP; Ren EC; Lin RTP; Renia L; Lye DC; Wang LF; Young BE
    Clin Infect Dis; 2022 Dec; 75(12):2088-2096. PubMed ID: 35543372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
    Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
    Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster.
    Peng P; Feng C; Hu J; He C; Deng H; Fan Q; Xiang J; Tang G; Jiang ML; Hu F; Li F; Wang K; Tang N; Tang XP; Huang A
    iScience; 2022 Nov; 25(11):105465. PubMed ID: 36338432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A
    Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines.
    Zhang B; Huo J; Huang Y; Teo SY; Duan K; Li Y; Toh LK; Lam KP; Xu S
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
    Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T
    Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals.
    Dai YC; Lin YC; Ching LL; Tsai JJ; Ishikawa K; Tsai WY; Chen JJ; Nerurkar VR; Wang WK
    Microbiol Spectr; 2023 Aug; 11(4):e0408122. PubMed ID: 37428104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.